Table 1.
Patient Demographics
| N | % | |
|---|---|---|
|
| ||
| Gender | ||
| Female | 43 | 37 |
| Male | 73 | 63 |
|
| ||
| Age | ||
| 24–88 | Mean 63 | |
|
| ||
| Site Of Metastatic Disease | ||
| Liver | 28 | 24 |
| Lung | 60 | 52 |
| Brain | 16 | 14 |
| Bone | 17 | 15 |
| Lymph | 49 | 42 |
| Other | 45 | 39 |
|
| ||
| Lines of treatment prior to Ipilimumab | ||
| 0 | 69 | 59 |
| 1 | 34 | 29 |
| 2+ | 13 | 11 |
|
| ||
| LDH at start of Ipilimumab | 195 (median) | |
|
| ||
| Lines of interval treatment between ipilimumab and PD-1 | ||
| 0 | 59 | 51 |
| >/=1 | 57 | 49 |
|
| ||
| Interval Radiation | 19 | 16 |
|
| ||
| Interval BRAF inhibitor | 22 | 19 |
|
| ||
| LDH at start of anti-PD-1 | 238 (median) | |
|
| ||
| Status at last follow-up | ||
| Alive | 77 | 66 |
| Dead | 39 | 34 |